查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1333923

阿黴素市場：現狀分析與預測（2022-2030）

Doxorubicin Market: Current Analysis and Forecast (2022-2030)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 144 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

由於技術進步和頻繁的產品發布，預計阿黴素市場在預測期內將以 7% 的複合年增長率強勁增長。例如，2019年12月，Capstone宣布鹽酸阿黴素脂質體注射液獲得 FDA 批准和歐盟許可。

根據劑型，市場分為凍乾粉針劑和阿黴素注射劑。凍乾粉細分市場在 2021 年獲得了主要份額。凍乾粉因其保質期長且易於運輸和儲存而被廣泛使用。而且，凍乾粉的高穩定性也是該細分市場在細分市場中佔有較大份額的重要原因。

根據應用，市場分為膀胱癌、卡波西肉瘤、白血病、淋巴瘤、乳腺癌等。在預測期內，阿黴素市場的白血病細分市場預計將以更高的複合年增長率增長。白血病的高患病率和該疾病病例的快速增加是推動該細分市場增長的關鍵因素。例如，美國癌症協會估計，2023 年將報告 59,610 例新的白血病病例和 23,710 例白血病死亡病例。

根據分銷渠道，市場分為醫院藥房、零售藥房和網上藥房。醫院藥房部門在 2021 年獲得了主要份額。這主要是因為患者更喜歡醫院藥房，因為它們擁有分發藥品所需的許可證，而且它們位於醫院內，更容易獲得藥品。

為了更好地了解該行業的市場採用情況，市場分為北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、意大利、西班牙、歐洲其他地區）、亞太地區（中國、日本、印度、韓國、澳大利亞等亞太地區國家）及世界其他地區。2021年阿黴素市場中，北美地區佔據壓倒性份額。這主要是由於老年人口的增加以及老年人癌症患病率的增加。此外，北美市場產品投放的增加和市場參與者的擴大也促進了北美阿黴素市場的增長。例如，根據人口研究所的數據，美國65歲及以上人口數量將從2018年的5200萬增加近一倍，達到2060年的9500萬，65歲及以上人口占總人口的比例將從16%增加到9500萬到2060年，預計將增加至23%。

目錄

第一章 市場介紹

  • 市場定義
  • 主要目的
  • 利益相關者
  • 限制

第二章 研究方法或假設

  • 調查過程
  • 調查方法
  • 受訪者簡介

第三章市場總結

第 4 章執行摘要

第五章新型冠狀病毒感染（COVID-19）對全球阿黴素市場的影響

第六章2020-2028年全球阿黴素市場收入

第七章 市場洞察的表述

  • 凍乾粉
  • 阿黴素注射液

第 8 章按應用劃分的市場洞察

  • 膀胱癌
  • 卡波西肉瘤
  • 白血病
  • 淋巴瘤
  • 乳腺癌
  • 其他

第 9 章按分銷渠道劃分的市場洞察

  • 醫院藥房
  • 零售藥店
  • 網上藥店

第10章按地區劃分的市場洞察

  • 北美阿黴素市場
    • 美國
    • 加拿大
    • 其他北美
  • 歐洲阿黴素市場
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 歐洲其他地區
  • 亞太阿黴素市場
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 韓國
    • 亞太地區其他國家
  • 其他地區阿黴素市場

第十一章阿黴素市場動態

  • 市場驅動力
  • 市場挑戰
  • 影響分析

第十二章阿黴素市場機會

第十三章阿黴素市場趨勢

第十四章需求側和供給側分析

  • 需求側分析
  • 供給側分析

第十五章價值鏈分析

第十六章價格分析

第十七章戰略洞察

第18章 競爭場景

  • 競爭格局
    • 波特五力分析

第十九章公司簡介

  • Intas Pharmaceuticals Ltd.
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Cadila Pharmaceuticals
  • Meiji Holdings Co., Ltd.
  • Johnson & Johnson Private Limited.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Baxter

第二十章 免責聲明

簡介目錄
Product Code: UMHE212094

Doxorubicin is an antibiotic with a broad antineoplastic activity that is obtained from a Streptomyces peucetius bacterium and is injected in the form of hydrochloride. This drug is used to treat different cancers such as kidney, ovarian, liver, ovarian, and others. This drug works by with interfering the DNA of cancerous cells and preventing them to grow and divide. The rising prevalence of cancerous diseases is the primary factor for the market growth of the doxorubicin market. For instance, according to the World Health Organisation (WHO), cancer is the primary cause of death worldwide accounting for 10 million deaths in 2020.

Doxorubicin Market is expected to grow at a strong CAGR of 7% during the forecast period owing the technological advancements and frequent product launches. For instance, In December 2019, Capstone announced the FDA Approval and EU Authorization of Doxorubicin Hydrochloride Liposome Injection.

Based on drug formulation, the market is segmented into lyophilized powder and doxorubicin injection. The lyophilized powder segment acquired a major share in 2021. The Lyophilized powders are commonly used because they have a longer shelf life and are easy to transport and stored. Further, the lyophilized powder is more stable which is also an important reason for the significant market share of the segment in the doxorubicin market.

Based on the application, the market is segmented into bladder cancer, kaposi sarcoma, leukemia, lymphoma, breast cancer, and others. The leukemia segment is expected to grow with a higher CAGR in the doxorubicin market during the forecast period. The prevalence of leukemia is high and the cases of the disease are growing at a rapid pace is an important factor responsible for the growth of the segment. For instance, as per the American Cancer Society, an estimated 59,610 new cases of leukemia and 23,710 deaths from leukemia will report in 2023.

Based on the distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment acquired a major share in 2021. This is mainly due to the hospital pharmacies having the necessary licenses for the distribution of these and patients also prefer hospital pharmacies due to their presence inside the hospital makes the drug availability easy.

For a better understanding of the market adoption of the industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Rest of World. North American region held dominant share in doxorubicin market in 2021. This is mainly due to the increasing prevalence of the geriatric population and the increased prevalence of cancer in them. Further, the increasing product launches and expansion of market players in the North American market are also responsible for the market growth of Doxorubicin in North America. For instance, as per the Population Reference Bureau, the number of Americans 65 and older is expected to nearly double, from 52 million in 2018 to 95 million in 2060, and the share of those 65 and older in the total population will increase from 16% to 23%.

Some of the major players operating in the market include: Intas Pharmaceuticals Ltd.; Cipla Inc.; Dr. Reddy's Laboratories Ltd.; Cadila Pharmaceuticals; Meiji Holdings Co., Ltd.; Johnson & Johnson Private Limited.; Novartis AG; Pfizer Inc.; Sun Pharmaceutical Industries Ltd.; and Baxter.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Doxorubicin Market
  • 2.2. Research Methodology of the Doxorubicin Market
  • 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL DOXORUBICIN MARKET COVID-19 IMPACT

6 GLOBAL DOXORUBICIN MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY DRUG FORMULATION

  • 7.1. Lyophilized Powder
  • 7.2. Doxorubicin Injection

8 MARKET INSIGHTS BY APPLICATION

  • 8.1. Bladder Cancer
  • 8.2. Kaposi Sarcoma
  • 8.3. Leukemia
  • 8.4. Lymphoma
  • 8.5. Breast Cancer
  • 8.6. Others

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

  • 9.1. Hospital Pharmacy
  • 9.2. Retail Pharmacy
  • 9.3. Online Pharmacy

10 MARKET INSIGHTS BY REGION

  • 10.1. North America Doxorubicin Market
    • 10.1.1. U.S.
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe Doxorubicin Market
    • 10.2.1. Germany
    • 10.2.2. UK
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific Doxorubicin Market
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Australia
    • 10.3.5. South Korea
    • 10.3.6. Rest of APAC
  • 10.4. Rest of the World Doxorubicin Market

11 DOXORUBICIN MARKET DYNAMICS

  • 11.1. Market Drivers
  • 11.2. Market Challenges
  • 11.3. Impact Analysis

12 DOXORUBICIN MARKET OPPORTUNITIES

13 DOXORUBICIN MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

  • 14.1. Demand Side Analysis
  • 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 PRICING ANALYSIS

17 STRATEGIC INSIGHTS

18 COMPETITIVE SCENARIO

  • 18.1. Competitive Landscape
    • 18.1.1. Porters Fiver Forces Analysis

19 COMPANY PROFILED

  • 19.1. Intas Pharmaceuticals Ltd.
  • 19.2. Cipla Inc.
  • 19.3. Dr. Reddy's Laboratories Ltd.
  • 19.4. Cadila Pharmaceuticals
  • 19.5. Meiji Holdings Co., Ltd.
  • 19.6. Johnson & Johnson Private Limited.
  • 19.7. Novartis AG
  • 19.8. Pfizer Inc.
  • 19.9. Sun Pharmaceutical Industries Ltd.
  • 19.10. Baxter

20 DISCLAIMER